-HOXD13 Fusion, /DN2, ALL, DN1, DN2, EITP ALL, EZH2, Early, Early Immature Thymocyte Precursor ALL, HOXD13, IDH1, IDH2 genes, Idh, Idh2, Idh2 DN1, Idh2 DN1/DN2 T-ALL, Idh2 leukemic cells, Idh2 mutation, Idh2 thymocytes, JAK3, KRAS, Mutant Idh2, NHD13, NUP98, PTPN11, SH2B3, T, T-ALL, T-cell leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, double-negative 1 (DN1) or DN2 thymocytes, early thymic precursor transcriptional signature, early/immature T-cell precursor (EITP) acute lymphoblastic leukemia, early/immature thymocyte precursor, enasidenib, hematologic malignancies, human, human early/immature T-cell precursor, immature T-cell leukemia, isocitrate, isocitrate dehydrogenase 1, isocitrate dehydrogenase 1 (IDH1) and IDH2 genes, leukemia, leukemic, leukemic cells, mice, mutant IDH2, myeloid and T-cell leukemias, myeloid cells, patients